Cancers, Vol. 15, Pages 4336: Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer & mdash;A Literature Review

Conclusion: The evaluation of tumor and LN staging and, hence, stratifying BC recurrence risk are decisive factors in guiding clinicians to optimize treatment decisions between the neoadjuvant versus adjuvant approaches. For each individual case, it is important to consider the most likely postsurgical outcome, since, if the patient does not obtain pCR following neoadjuvant treatment, they are eligible for adjuvant T-DM1 in the case of residual disease. This review of HER2-positive female BC outlines suitable neoadjuvant and adjuvant systemic treatment strategies for guiding clinical decision making around the selection of an appropriate therapy.

Source: Cancers - August 30, 2023 Category: Cancer & Oncology Authors: Danilo Giffoni de Mello Morais Mata Rania Chehade Malek B. Hannouf Jacques Raphael Phillip Blanchette Abdullah Al-Humiqani Monali Ray Tags: Review Source Type: research